RxDoctor Payments Data

Christina Johnson

Nurse Practitioner · Crestview, FLNPI 1740227503

Payments from drug & device makers

$750in general payments, 2019–2025

Across 43 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$216
  • GSK$168
  • Lilly USA, LLC$74
  • Johnson & Johnson$57
  • AbbVie$54
  • Merck$49
  • plus $132 from 5 others

What the payments were for

  • Food & beverage$750100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$750 in reported general payments places this provider in the 70th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$118,754
Medicare patients
135
Services billed
1,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$53,826
XareltoRivaroxaban47$29,052
TrulicityDulaglutide21$18,072
JanuviaSitagliptin Phosphate26$13,796
MyrbetriqMirabegron20$10,090
EntrestoSacubitril/Valsartan11$5,059
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,873
Gabapentin194$3,830
Sucralfate58$3,426
Potassium Chloride159$3,053
Albuterol Sulfate HfaAlbuterol Sulfate53$2,958
Carbamazepine ErCarbamazepine18$2,795
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,509
Imatinib Mesylate11$2,435
Montelukast Sodium124$2,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$53,82671 claims
Johnson & JohnsonXarelto$57$29,05247 claims
Lilly USA, LLCTrulicity$74$18,07221 claims
MerckJanuvia$49$13,79626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Crestview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →